MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cncr.26708

Медицинская библиотека · Cancer · 2011

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.

Ferrario Andrea, Pulsoni Alessandro, Olivero Barbara, Rossi Giuseppe, Vitolo Umberto, Tedeschi Alessandra, Merli Francesco, Rigacci Luigi, Stelitano Caterina, Goldaniga Maria, Mannina Donato, Musto Pellegrino, Rossi Francesca, Gamba Enrica, Baldini Luca

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell proliferations for which treatment has not been defined to date.

METHODS

In this phase 2 study of patients with advanced INFL, the authors evaluated the efficacy and safety of first-line rituximab, fludarabine, and cyclophosphamide (FCR) as induction immunochemotherapy (rituximab 375 mg/m(2) intravenously on day 1 of each cycle and on days 1 and 14 of cycles 4 and 5; fludarabine 25 mg/m(2) intravenously on days 2-4, cyclophosphamide 250 mg/m(2) intravenously on Days 2-4) every 28 days for 6 cycles followed by a maintenance phase with 4 infusions of rituximab (375 mg/m(2) intravenously on day 1) every 2 months for responders.

RESULTS

Forty-seven patients were enrolled. Among 46 evaluable patients (28 men; median age, 59 years), 19 were diagnosed with lymphoplasmacytic lymphoma, 21 were diagnosed with small lymphocytic lymphoma, and 6 were diagnosed with nodal marginal zone lymphoma. The overall response rate after maintenance was 89.1% with a 67.4% complete remission (CR) rate (CR/unconfirmed CR) and a 21.7% partial response rate. After a median follow-up of 40.9 months, the failure-free survival and progression-free survival rates both were 90.1%, and the overall survival rate was 97.4%. The main toxicity was hematologic, and related grade 3 and 4 neutropenia was observed in 55.3% of patients.

CONCLUSIONS

FCR induction therapy followed by a short maintenance phase is a highly effective regimen with acceptable toxicity.

Для цитирования: Ferrario Andrea, Pulsoni Alessandro, Olivero Barbara, Rossi Giuseppe, Vitolo Umberto, Tedeschi Alessandra, Merli Francesco, Rigacci Luigi, Stelitano Caterina, Goldaniga Maria, Mannina Donato, Musto Pellegrino, Rossi Francesca, Gamba Enrica, Baldini Luca. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.. Cancer. 2011. DOI: 10.1002/cncr.26708.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.